Abstract
This review focuses on the possibilities for intraoperative processing and isolation of autologous cells, particularly atrial appendage-derived cells (AADCs) and cellular micrografts, and their straightforward use in cell transplantation for heart failure therapy. We review the potential of autologous tissues to serve as sources for cell therapy and consider especially those tissues that are used in surgery but from which the excess is currently discarded as surgical waste. We compare the inculture expanded cells to the freshly isolated ones in terms of evidence-based cost-efficacy and their usability as gene- and RNA therapy vehicles. We also review how financial and authority-based decisions and restrictions sculpt the landscape for patients to participate in academic-based trials. Finally, we provide an insight example into AADCs isolation and processing for epicardial therapy during coronary artery bypass surgery.
Keywords: Autologous cell transplantation, Gene therapy, RNA therapy, Minimal cell manipulation, Cardiac micrografts.
Current Gene Therapy
Title:Rational Autologous Cell Sources For Therapy of Heart Failure - Vehicles and Targets For Gene and RNA Therapies
Volume: 16 Issue: 1
Author(s): Milla Lampinen, Antti Vento, Jari Laurikka, Johanna Nystedt, Eero Mervaala, Ari Harjula and Esko Kankuri
Affiliation:
Keywords: Autologous cell transplantation, Gene therapy, RNA therapy, Minimal cell manipulation, Cardiac micrografts.
Abstract: This review focuses on the possibilities for intraoperative processing and isolation of autologous cells, particularly atrial appendage-derived cells (AADCs) and cellular micrografts, and their straightforward use in cell transplantation for heart failure therapy. We review the potential of autologous tissues to serve as sources for cell therapy and consider especially those tissues that are used in surgery but from which the excess is currently discarded as surgical waste. We compare the inculture expanded cells to the freshly isolated ones in terms of evidence-based cost-efficacy and their usability as gene- and RNA therapy vehicles. We also review how financial and authority-based decisions and restrictions sculpt the landscape for patients to participate in academic-based trials. Finally, we provide an insight example into AADCs isolation and processing for epicardial therapy during coronary artery bypass surgery.
Export Options
About this article
Cite this article as:
Lampinen Milla, Vento Antti, Laurikka Jari, Nystedt Johanna, Mervaala Eero, Harjula Ari and Kankuri Esko, Rational Autologous Cell Sources For Therapy of Heart Failure - Vehicles and Targets For Gene and RNA Therapies, Current Gene Therapy 2016; 16 (1) . https://dx.doi.org/10.2174/1566523216666160104141809
DOI https://dx.doi.org/10.2174/1566523216666160104141809 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Acute Severe Arterial Hypertension: Therapeutic Options
Current Drug Targets Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients
Current Vascular Pharmacology Calcium Channel Blockers - Benefits Upon Vascular Biology in Hypertensive Patients
Cardiovascular & Hematological Agents in Medicinal Chemistry Tityus serrulatus Scorpion Venom and Toxins: An Overview
Protein & Peptide Letters The Role of Oxidative Stress in the Pathogenesis of Type 2 Diabetes Mellitus Micro- and Macrovascular Complications: Avenues for a Mechanistic-Based Therapeutic Approach
Current Diabetes Reviews Diabetes and Atherosclerosis: Old Players in a New Field, Osteoporosis
Current Vascular Pharmacology The Current and Future Therapies for Human Osteosarcoma
Current Cancer Therapy Reviews An Overview of Phytotherapeutic Approaches for the Treatment of Benign Prostatic Hyperplasia
Mini-Reviews in Medicinal Chemistry Pharmacological Implications of MMP-9 Inhibition by ACE Inhibitors
Current Medicinal Chemistry Impact of Antihypertensive Drug Use on Bone Mineral Density and Osteoporotic Fracture - From an Epidemiological Perspective
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Enzyme Replacement Therapy in Fabry Disease: Influence on Cardiac Manifestations
Current Medicinal Chemistry The Role of AGEs in Cardiovascular Disease
Current Pharmaceutical Design Update on AKI Biomarker Patents
Current Biomarkers (Discontinued) HIF-1α and Calcium Signaling as Targets for Treatment of Prostate Cancer by Cardiac Glycosides
Current Cancer Drug Targets Long-term Results After Transcatheter Aortic Valve Implantation: What do we Know Today?
Current Cardiology Reviews Targeting Nrf2 in Protection Against Renal Disease
Current Medicinal Chemistry Pneumonia in the Elderly
Current Respiratory Medicine Reviews Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Treatment of Hypertension: Should they be Used Together?
Current Vascular Pharmacology Phosphoproteome and Kinome Analysis: Unique Perspectives on the Same Problem
Current Analytical Chemistry B7-H3-targeted Radioimmunotherapy of Human Cancer
Current Medicinal Chemistry